AnalystConsensusTarget updated the narrative for BSX

Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.

Analyst Commentary

Following Boston Scientific's recent performance and strategic developments, analysts have issued a range of updated perspectives on the company's outlook. Their commentary reflects both confidence in the business's execution and some caution regarding future challenges.

• Bullish analysts have continued to raise price targets, citing sustained momentum in quarterly results and upward revisions to guidance for organic growth and earnings per share.
• Strong performance in the Watchman franchise was identified as an area of acceleration. This contributes to confidence in the company’s ability to deliver upside beyond revised guidance.
• Recent acquisitions, such as the agreement to acquire Nalu Medical, are seen as strategically sound and leverage Boston Scientific’s track record in building value through early-stage investments and complementary M&A.
• The company’s three-year plan, projecting organic growth of 10%, is considered impressive and positions Boston Scientific to deliver above-average sales and EPS growth compared to large-cap MedTech peers.

• Bearish analysts caution that sales growth rates may moderate in 2026 compared to 2025. This could weigh on valuation as expectations adjust.
• There are concerns about Boston Scientific’s stock being expensive relative to sector peers, potentially limiting share price upside from current levels.
• While recent quarters have addressed some competitive fears, execution challenges in specific segments, such as electrophysiology, remain on investors’ radars.

What's in the News

• Truist raised Boston Scientific's price target to $130 from $129 after a strong Q3 earnings beat. The firm highlighted accelerated growth in the Watchman franchise and expressed confidence in further upside to updated guidance (Truist).
• Oppenheimer increased its price target for Boston Scientific to $118 from $110 following the Q2 report, maintaining a Perform rating (Oppenheimer).
• Boston Scientific announced guidance for Q4 and full year 2025, projecting net sales growth of 14.5% to 16.5% for Q4 and approximately 20% for the full year on a reported basis. GAAP EPS is expected in the range of $1.97 to $2.01 for 2025 (Company guidance).
• The company recently held an Analyst/Investor Day to review financial goals and long-term growth strategies (Company event).

Valuation Changes

• The consensus analyst price target has risen slightly to $126.14 from $124.53.
• The discount rate increased marginally, now at 7.60% compared to 7.56% previously.
• Revenue growth projections have edged lower, now estimated at 11.04%, down from 11.14%.
• The net profit margin improved, rising to 19.27% from 18.71%.
• The future P/E ratio has fallen moderately, now at 46.32x versus the previous 49.09x.